Ғылым және денсаулық сақтау

Ахметжан М. Галимжанов, http://orcid.org/0000-0002-1605-9512 

Семей Мемлекеттік Медицина Университеті,

Терапия бойынша интернатура кафедрасы,

Семей қ., Қазақстан.

1. Кардиология. Национальное руководство: краткое издание/ под ред. Ю.Н. Беленкова, Р.Г. Оганова. - М.: ГЭОТАР-Медиа, 2012. - 864 с.
2. Национальный центр экспертизы лекарственных средств, изделий медицинского назначения и медицинской техники МЗСР РК. Государственный реестр. http://www.dari.kz/category/gos_reestr_excel. (Дата обращения: 15 декабря 2016 года).
3. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–1420.
4. Chern-En Chiang, Tsu-Juey Wu, Kwo-Chang Ueng et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. Journal of the Formosan Medical Association (2016) 115, 893e952. http://dx.doi.org/10.1016/j.jfma.2016.10.005.  (Accessed on January 25, 2017).
5. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837–847.
6. Connolly S., Pogue J., Hart R. et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–1912.
7. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R. et al. AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–817.
8. Connolly S.J., Pogue J., Eikelboom J., Flaker G., Commerford P. et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029–2037.
9. Dariush Mozaffarian et al. Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association. Circulation. 2015; 131: e 535. DOI: 10.1161/CIR.0000000000000219.
10. Dewilde W.J., Oirbans T., Verheugt F., Kelder J.C. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107–1115.
11. Freeman J.V., Simon D.N., Go A.S., Spertus J., Fonarow G.C. et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015;8:393–402.
12. Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D. et al Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–2104.
13. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–867.
14. Health and Social Care Information Centre. (2015). Quality and Outcomes Framework (QOF) - 2014-15. Available: https://docviewer.yandex.com/?url=http%3A%2F%2Fcontent.digital.nhs.uk%2Fcatalogue%2FPUB18887%2Fqof-1415-Report%2520v1.1.pdf&name =qof-1415-Report%20v1.1.pdf&lang=en&c= 584053b173bc&page=1. (Last accessed 15 December 2016)
15. Jamshed D., Abhay B., Abraham O. et al. The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian heart journal 67 (2015) s13 – s34. http://dx.doi.org/10.1016/j.ihj.2015.10.380 . (Accessed on January 25, 2017).
16. John Camm A., Gregory Y.H. Lip, De Caterina R., Savelieva I., Atar D. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal (2012) 33, 2719–2747. doi:10.1093/eurheartj/ehs253
17. Kamalbekova G. and Kalieva M. Evidence-based medicine Training: Kazakhstan experience. International Journal of Risk & Safety in Medicine 27 (2015) S95–S96 DOI 10.3233/JRS150705 IOS Press.
18. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Journal. doi:10.1093/eurheartj/ehw210
19. Kotecha D., Holmes J., Krum H., Altman D.G., Manzano L. et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235–2243.
20. Kotecha D., Manzano L., Krum H., Rosano G., Holmes J. et al. Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of b blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016;353:i1855.
21. Kuramatsu J.B., Gerner S.T., Schellinger P.D., Glahn J., Endres M. et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulationrelated intracerebral hemorrhage. JAMA 2015;313:824–836.
22. Mant J., Hobbs F.D., Fletcher K., Roalfe A., Fitzmaurice D. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503.
23. Mikkelsen A.P., Lindhardsen J., Lip G.Y., Gislason G.H., Torp-Pedersen C.et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012;10:1745–1751.
24. Nielsen P.B., Larsen T.B., Skjoth F., Gorst-Rasmussen A., Rasmussen L. et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 2015;132:517–525.
25. Owolabi et al. Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism. BMJ Glob Health. 2016 October 5; 1(3): . doi:10.1136/bmjgh-2016-000105.
26. Piccini J.P., Hellkamp A.S., Lokhnygina Y., Patel M.R., Harrell F.E. et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014;3:e000521.
27. Pinyol C. et al. A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. Cardiol Ther (2016) 5:171–186. Published online: July 25, 2016.
28. Reiffel J.A. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014 Apr;127(4):e15-6. doi: 10.1016/j.amjmed.2013.06.002. (abstract)
29. Royal College of Physicians Sentinel Stroke National Audit Programme (SSNAP). Clinical audit April - June 2015 report prepared by Royal College of Physicians, Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party.
30. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 955–962.
31. Secemsky E. A., Butala N. M., Kartoun U., Mahmood S., Wasfy J. H. et al. Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2016;5:e004310; originally published October 17, 2016; doi: 10.1161/JAHA.116.004310
32. Stroke Association. State of the Nation. Stroke statistics. January 2016.  https://www.stroke.org.uk/sites/default/files/state_of_the_nation_2016_110116_0.pdf. (Accessed on December 15, 2016)
33. VanWalraven C., Hart R.G., Connolly S., Austin P.C., Mant J. et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009;40:1410–1416.
34. Wallentin L., Yusuf S., Ezekowitz M.D., Alings M., Flather M. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–983.
35. World Health Organization. Kazakhstan: WHO statistical profilе. http://who.int/gho/countries/kaz.pdf?ua=1. Last updated: January 2015. (Accessed on December 15, 2016)
36. Wynn G.J., Todd D.M., Webber M., Bonnett L., McShane J. et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014;16: 965–972.
37. Yasaka M., Gregory Y.H. Impact of Non-Vitamin K. Antagonist Oral Anticoagulants on Intracranial Bleeding in Asian Patients With Non-Valvular Atrial Fibrillation. Circulation Journal Vol.78, October 2014. doi: 10.1253/circj.CJ-14-0720.
38. Zheng Z., Jayaram R., Jiang L., Emberson J., Zhao Y. et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016;374:1744–1753.